Management of transitional-cell carcinoma of the renal pelvis and ureter.
Transitional-cell carcinoma of the renal pelvis or ureter is a relatively rare disease. Several risk factors are smoking, occupational carcinogens, analgesic abuse or Balkan nephropathy. The grade and stage of the disease have the most significant impact on the outcome. The treatment of renal pelvis and ureter tumours is open or laparoscopic surgery varying from conservative to more extensive surgical procedures, i.e. radical nephroureterectomy including removal of the contents of Gerota's fascia with ipsilateral ureter and a cuff of bladder at its distal extent. Most available data are from retrospective studies and surgery is the mainstay of treatment. Chemotherapy and/or radiation therapy are possible adjuvant or primary treatment for selected patients; however, prospective studies are needed to confirm their use.
Ozsahin
M
M
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, CHUV, Lausanne, Switzerland. mahmut.ozsahin@chuv.ch
Ugurluer
G
G
Zouhair
A
A
D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D007682:Kidney Pelvis / Q000473:pathology / Q000601:surgery; D008297:Male; D009367:Neoplasm Staging; D009392:Nephrectomy; D014516:Ureteral Neoplasms / Q000473:pathology / Q000601:surgery*